1. known history of ivermectin allergy 2. hypersensitivity to any component of stromectol® 3. covid-19 pneumonia identified by chest x-ray or high resolution ct scan 4. fever or cough present for more than 7 days 5. positive igg against sars-cov-2 by rapid test if available on baseline screening. 6. the following co-morbidities (or any other disease that, in the opinion of the investigators, might interfere with the study: 1. immunosuppression 2. hiv 3. acute or chronic renal failure 4. current neoplasm 7. alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5 x upper limit of normal within the prior 6 months if available or clinical evidence of liver failure with jaundice, ascites, encephalopathy. 8. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

1. known history of ivermectin allergy 2. hypersensitivity to any component of stromectol® 3. covid-19 pneumonia identified by chest x-ray or high resolution ct scan 4. fever or cough present for more than 7 days 5. positive igg against sars-cov-2 by rapid test if available on baseline screening. 6. the following co-morbidities (or any other disease that, in the opinion of the investigators, might interfere with the study: 1. immunosuppression 2. hiv 3. acute or chronic renal failure 4. current neoplasm 7. alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5 x upper limit of normal within the prior 6 months if available or clinical evidence of liver failure with jaundice, ascites, encephalopathy. 8. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

known history of ivermectin allergy hypersensitivity to any component of stromectol® covid-19 pneumonia identified by chest x-ray or high resolution ct scan fever or cough present for more than 7 days positive igg against sars-cov-2 by rapid test if available on baseline screening. the following co-morbidities (or any other disease that, in the opinion of the investigators, might interfere with the study: immunosuppression hiv acute or chronic renal failure current neoplasm alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal within the prior 6 months if available or clinical evidence of liver failure with jaundice, ascites, encephalopathy. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

known history of ivermectin allergy hypersensitivity to any component of stromectol® covid-19 pneumonia identified by chest x-ray or high resolution ct scan fever or cough present for more than 7 days positive igg against sars-cov-2 by rapid test if available on baseline screening. the following co-morbidities (or any other disease that, in the opinion of the investigators, might interfere with the study: immunosuppression hiv acute or chronic renal failure current neoplasm alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal within the prior 6 months if available or clinical evidence of liver failure with jaundice, ascites, encephalopathy. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

1. known history of ivermectin allergy 2. hypersensitivity to any component of stromectol® 3. covid-19 pneumonia identified by chest x-ray or high resolution ct scan 4. fever or cough present for more than 7 days 5. positive igg against sars-cov-2 by rapid test if available on baseline screening. 6. the following co-morbidities (or any other disease that, in the opinion of the investigators, might interfere with the study: 1. immunosuppression 2. hiv 3. acute or chronic renal failure 4. current neoplasm 7. alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal within the prior 6 months if available or clinical evidence of liver failure with jaundice, ascites, encephalopathy. 8. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

1. known history of ivermectin allergy 2. hypersensitivity to any component of stromectol® 3. covid-19 pneumonia identified by chest x-ray or high resolution ct scan 4. fever or cough present for more than 7 days 5. positive igg against sars-cov-2 by rapid test if available on baseline screening. 6. the following co-morbidities (or any other disease that, in the opinion of the investigators, might interfere with the study: 1. immunosuppression 2. hiv 3. acute or chronic renal failure 4. current neoplasm 7. alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal within the prior 6 months if available or clinical evidence of liver failure with jaundice, ascites, encephalopathy. 8. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.